MA Governor Announces $500-Million Investment in Life-Science Industry

News
Article

Charlie Baker announced a plan to invest up to $500 million in the MA life-science industry.

On June 19, 2017, Massachusetts governor Charlie Baker announced a plan to invest up to $500 million in the state’s life-science industry. The five-year plan proposes strategic investments in public infrastructure, R&D, workforce training and education, and includes up to $295 million in capital authorization and up to $150 million job-creating tax incentives. The funding will be managed by the Massachusetts Life Sciences Center (MLSC) and Baker will further discuss the plan during the BIO International Convention in San Diego, CA.  

According to a statement, the five-year, $295-million bond authorization in the proposal would provide capital funding that will enable the state to strengthen the ecosystem through collaborations that maximize third-party investments and sharpen MA’s competitive edge.

In addition to seeking new capital authorization for the MLSC, the administration’s legislative proposal also extends and expands the authorization of a key state tax credit that finances job growth. The proposal would permit the MLSC to award tax incentives for an additional 10 years and increases the MLSC’s current annual statutory cap up to $30 million on tax credit awards.

“This proposal will build upon previous investment by the Baker-Polito Administration that has propelled Massachusetts to the top of so many national lists including innovation, growth potential, and R&D investment,” said Executive Office of Housing and Economic Development Secretary, Jay Ash in a statement. It will also allow the state to remain competitive, enhance workforce training opportunities, leverage tax incentives to encourage new job creation, and launch infrastructure projects that will reinforce the global competitiveness of R&D centers and the development of a robust biomanufacturing sector.”

Source: Governor Charlie Baker

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content